Diagnostics
Optimizing Portal Venous Phase Acquisition Quality of Contrast-Enhanced CT in Oncology
Door Amir Zemmouri, Marcus Talke, Marie Porte en 14 anderen.
Inhoud in het Engels
Abstract
Background
Portal venous phase (PVP) contrast-enhanced CT is a cornerstone for response assessment in early-phase oncology trials, yet contrast-enhancement phase timing remains insufficiently monitored across sites. We assessed PVP timing using a validated artificial intelligence (AI) quality control tool (CECT-QC).
Methods
In this retrospective multicenter study, 402 CT examinations from 402 patients enrolled in phase I oncology trials across three European institutions were analyzed using CECT-QC, which quantifies aortic and portal venous enhancement to classify contrast-enhancement phase. The primary analysis included 335 standard CT examinations. Optimal PVP classification was compared (i) across institutions, (ii) before vs. after French regulatory changes impacting contrast delivery, and (iii) across scanner technologies (photon-counting CT [PCCT] vs. standard CT).



